Sodium fluoride

Sodium fluoride is a radiopharmaceutical compound indicated in molecular imaging diagnostic procedures in oncology and traumatology. Some of the special indications of sodium fluoride PET include specific cases of paediatric trauma and bone and other metastases, in which sodium fluoride provides high image resolution.

Fluorocholine

Fluorocholine is a radiopharmaceutical compound indicated in molecular imaging diagnostic procedures in oncology. The diagnostic objective of fluorocholine PET is to visualize increased choline uptake by specific organs and tissues. Some of the most common indications are for prostate cancer, cases of increased prostate specific antigen (PSA) serum concentration, liver cancer and certain gliomas.

18F-Prostate specific membrane antigen

18F-Prostate specific membrane antigen or (18F)-PSMA is a radiopharmaceutical compound indicated in molecular imaging diagnostic procedures in oncology. The level of expression of PSMA is of prognostic value in the evolution of prostate cancer, since it is a transmembrane protein present in all the prostate gland tissues. (18F)-PSMA PET delivers important advantages in terms of imaging the sensitivity and quality in patients with prostate cancer.

18F-TAU

The TAU tracer is a radiopharmaceutical compound indicated in molecular imaging diagnostic procedures in neurology. More specifically, it is used to obtain PET images of TAU protein plaque density in the brain of adult patients with cognitive impairment being evaluated for Alzheimer's disease and other causes of cognitive deterioration.

Fluoromisonidazole

Fluoromisonidazole (FMISO) is a radiopharmaceutical compound indicated in molecular imaging diagnostic procedures in oncology. FMISO PET makes it possible to detect situations of regional hypoxia caused by the cancer process. In certain diseases, hypoxia is an important survival and tumour control prognostic factor. Thus, FMISO PET can provide a great deal of information in these situations.

Fluorothymidine

Fluorothymidine (FLT) is a radiopharmaceutical compound indicated in molecular imaging diagnostic procedures in oncology. Fluorothymidine accumulates in proliferating cells, indicating activity of the thymidine kinase enzyme. Cell division can be characterized by this enzyme’s activity. FLT PET shows how the tumour is responding to cytostatic therapies.

18F-MPPF

This radiopharmaceutical compound is indicated in molecular imaging diagnostic procedures in neurology. The 18F-MPPF compound binds specifically to the serotonin 1-A receptor. The diagnostic objective of 18F-MPPF PET is to assess serotonin neuroreceptor binding differences.